Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 735 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Biliary Diseases Clear all

Conditions: Cholestasis
Interventions: Intralipid 20% I.V. Fat Emulsion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Gainesville, Florida • Ann Arbor, Michigan + 2 more

Conditions: Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC)
Interventions: Cilofexor; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 4
States / cities: Miami, Florida • Orlando, Florida • Knoxville, Tennessee + 1 more

Conditions: Pancreaticobiliary Cancers, Jaundice, Bile Duct Obstruction
Interventions: ERCP, EUS FNA; Procedure
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
Interventions: CTX-009, Paclitaxel; Drug
Lead sponsor: Compass Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 30 more

Conditions: Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer, Liver Metastases
Interventions: RO7119929, Tocilizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
Interventions: becatecarin; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2005
U.S. locations: 3
States / cities: Birmingham, Alabama • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Primary Sclerosing Cholangitis
Interventions: Mitomycin C, Normal saline; Drug
Lead sponsor: Li, Zhiping, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cholelithiasis, Cholecystitis, Pancreatitis Biliary, Colic of Gallbladder Without Mention of Cholecystitis
Interventions: Indocyanine Green (ICG); Drug
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Biliary Tract Diseases, Pancreatic Diseases
Interventions: Endoscope assisted endotracheal intubation [EAEI]; Procedure
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Stanford, California

Conditions: Parenteral Nutrition Associated Liver Disease PNALD, Cholestasis
Interventions: Omegaven™; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Symptomatic Gallbladder Disease
Interventions: Cholecystectomy; Procedure
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 7
States / cities: Pasadena, California • Lake Worth, Florida • Miami, Florida + 4 more

Conditions: Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome, Meckel-Gruber Syndrome, Congenital Hepatic Fibrosis, Caroli Syndrome, Oro-Facial-Digital Syndrome Type I, Nephronophthisis, Glomerulocystic Kidney Disease
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2030
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Biliary Stones, Cholangiocarcinoma, Intrahepatic, Biliary Stricture, Cholelithiasis, Choledocholithiasis
Interventions: Percutaneous cholangiopancreatoscopy; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 679 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cholestasis, Red Cell Membrane and Enzyme Abnormalities
Interventions: ektacytometry of red blood cells; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
Interventions: [18F]FP-R01-MG-F2; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cholestasis, Growth Failure
Interventions: SMOFlipid; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 14 Days to 1 Year
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Gallbladder Dyskinesia
Interventions: Laparoscopic Cholecystectomy, amitriptyline, low-fat and low cholesterol diet; Procedure · Drug · Other
Lead sponsor: CAMC Health System; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Charleston, West Virginia

Conditions: Biliary Disease, Pancreatitis, Gastrointestinal Neoplasms
Interventions: clinical course; Other
Lead sponsor: University of Southern California; Other
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Gallbladder Cancer
Interventions: irinotecan hydrochloride; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 20
States / cities: Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 17 more

Conditions: Solid Organ Cancers
Interventions: GL-ONC1; Biological
Lead sponsor: Andrew Lowy; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Primary Biliary Cholangitis (PBC)
Interventions: Elafibranor 80 mg, Elafibranor 120 mg, Placebo; Drug
Lead sponsor: Genfit; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 13
States / cities: Phoenix, Arizona • Miami, Florida • Weston, Florida + 9 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, Adult, G12D Mutated KRAS
Interventions: VS-7375, Cetuximab, Carboplatin + Pemetrexed + Pembrolizumab, Gemcitabine + Nab-paclitaxel, Pembrolizumab, Defactinib, Midazolam, Repaglinide; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 616 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 10 more

Conditions: Hepatobiliary Diseases
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 65 Years
Enrollment: 430 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus, Squamous Cell Car. - Esophagus, Urothelial Carcinoma (UC), Bladder Cancer, Mesothelioma, Pleural Mesothelioma, Peritoneal Mesothelioma, Non-Small Cell Lung Cancer NSCLC, Pancreatic Cancer, Biliary Tract Carcinoma
Interventions: IDE892, IDE397; Drug
Lead sponsor: IDEAYA Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 23
States / cities: Goodyear, Arizona • Phoenix, Arizona • Duarte, California + 19 more

Search by objective public record fields.

Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

Endoscopic Ultrasound Versus Endoscopic Retrograde Cholangiopancreatography (ERCP) Tissue Sampling for the Diagnosis of Suspected Pancreatico-Biliary Cancer

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases

Rebeccamycin Analogue in Treating Patients With Advanced Liver and/or Biliary Cancer

Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

The Use of Fluorescent Imaging for Intraoperative Cholangiogram During Laparoscopic Cholecystectomy

Comparison of Standard and Endoscope Assisted Endotracheal Intubation

Evaluation of Omegaven™ Parenteral Nutrition in Patients With Total Parenteral Nutrition (TPN)-Induced Cholestasis

Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy

ARPKD Database Study

Percutaneous Cholangiopancreatoscopy Registry

Osmotic Fragility in Red Blood Cells of Pediatric Patients With Cholestatic Liver Disease

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury

Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia

Los Angeles Prospective GI Biliary and EUS Series

Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer

GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers

Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors